$CRMD Key regulatory decisions scheduled for August: Can Second Time Be Charm For CorMedix? Company: CorMedix, Inc. (NASDAQ: CRMD) Type of Application: NDA Candidate: defencath Indication: catheter-related blood stream infections Date: August 29 (estimated) Defencath is to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter-related bloodstream infections. The original application was issued a CRL in March 2021. CorMedix filed a resubmission in late February, and it was accepted as a complete Class 2 response, with a six-month review cycle, in late March. The new PDUFA date could potentially be on August 29.